NCT01882062 (TRIHEP2) is a Phase 2 clinical trial of Triheptanoin 1g/kg/day in Huntington Disease, sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

Who is sponsoring NCT01882062?

NCT01882062 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France.

What drugs are being tested in NCT01882062?

Interventions in NCT01882062: Triheptanoin 1g/kg/day.

What condition does NCT01882062 study?

NCT01882062 studies Huntington Disease.

Is NCT01882062 still recruiting?

NCT01882062 is currently completed. Last updated 6 March 2026.

Are results published for NCT01882062?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-03-06 · How we verify

NCT01882062: TRIHEP2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease

Completed Phase 2 Results posted Last updated 6 March 2026

What this trial tests

Phase 2 trial testing Triheptanoin 1g/kg/day in Huntington Disease in 10 participants. Completed in 1 July 2013.

Timeline

1 May 2013

Primary endpoint
1 July 2013

1 July 2013

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 May 2013
Primary completion	1 July 2013
Estimated completion	1 July 2013
Sites	1 location across France

Drugs / interventions tested

Triheptanoin 1g/kg/day — full drug profile →

Conditions studied

Huntington Disease — all drugs for Huntington Disease →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

18 and older, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Ratio of Inorganic Phosphate (Pi) Over Phosphocreatine (PCr): Pi/PCr
Time frame: visit 1 (baseline), visit 2 (after 1 month of treatment)
The Pi/PCr Ratio is a measure of brain metabolism and it is an index of mitochondrial oxidative regulation. A 6-cm 31P transmit/receive surface coil (RAPID Biomedical GmbH, Rimpar, Germany) was used to collect free induction decays for 4 minutes at rest, 8 minutes during visual activation with 6-Hz red/black checkerboard flashes, and 8 minutes after stimulation. Subjects were able to focus on the

Sponsor's own description

The purpose of this project is to study the efficacy of an anaplerotic treatment on brain energy profile evolution at an early stage of the Huntington disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Triheptanoin improves brain energy metabolism in patients with Huntington disease.
Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, et al · · 2015 · cited 78× · PMID 25568297 · DOI 10.1212/wnl.0000000000001214
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases.
Stanga S, Caretto A, Boido M, Vercelli A. · · 2020 · cited 73× · PMID 32466216 · DOI 10.3390/ijms21103719

Verify or expand the search:

Other recruiting trials for Huntington Disease

Currently open trials in the same condition.

NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
NCT06774443 — Hinting Task for Huntington's Disease · recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting

Other Institut National de la Santé Et de la Recherche Médicale, France trials

Trials by the same sponsor.

NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01882062 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
Last refreshed: 6 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01882062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing